Tissue-based Drug Discovery / Histopathology

In the pre-clinical development of a potential new drug, one of the most expensive aspect of its safety assessment is the screening of tissue slides. Conventional manual screening processes are labor intensive and costly. They often run a significant risk of human error in identifying efficacy and toxicity profiles and, at the same time, there is a shortage of pathologists to carry out the task. Compounding the challenge, statutory regulations are becoming increasingly stringent with a demand for more accurate and consistent data.

All these factors together create a bottleneck that slows time to market and heightens failure rates in a drug candidate’s clinical trials.

Automated digital pathology solutions need to deliver accurate and consistent results. A wide variety of decisive morphological parameters need to be measured and exported including spectral statistics, shape, size, position, texture and relations to neighbor objects, sub objects and super objects. Image analysis tasks of any size need to be handled quickly, accurately and consistently.

Definiens’ technology is at the heart of automated digital pathology applications that deliver accurate and consistent results. They extract objects and create hierarchical levels of classification representing networked objects of interest on different scales. Pharmaceutical and biotech companies around the world use our image analysis platforms Definiens Enterprise Image Intelligence™ Suite and Definiens XD to develop applications for analyzing a wide range of tissue slides including lung, liver, kidney, brain, skin etc.

For more information on Definiens applications for automated digital pathology please visit our Definiens Tissue Studio™ pages. 

 Definiens is proud to be a founding member of the Digital Pathology Association.